BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi

被引：1
|
作者：
Dudnik, E. [1 ]
Bar, J. [2 ]
Kuznetsov, T. [2 ]
Moskovitz, M. [3 ]
Dudnik, J. [4 ]
Shochat, T. [5 ]
Zer, A. [1 ]
Urban, D. [2 ]
机构：
[1] Rabin Med Ctr, Davidoff Canc Ctr, Thorac Canc Serv, Petah Tiqwa, Israel
[2] Chaim Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel
[3] Rambam Hlth Care Campus, Thorac Canc Serv, Haifa, Israel
[4] Soroka Univ Med Ctr, Inst Canc, Beer Sheva, Israel
[5] Rabin Med Ctr, Stat Consulting Unit, Petah Tiqwa, Israel
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
BAP1; immune check-point inhibitors; poly (ADP-ribose) polymerase inhibitors;
D O I：
10.1016/j.jtho.2019.08.1632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-14
引用
收藏
页码：S760 / S760
页数：1
相关论文
共 50 条
  • [31] BAP1 germline variations in Finnish patients with malignant mesothelioma
    Repo, Pauliina
    Staskiewicz, Aleksandra
    Sutinen, Eva
    Ronty, Mikko
    Kivela, Tero T.
    Myllarniemi, Marjukka
    Turunen, Joni A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 372 - 372
  • [32] Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion
    Taylor, Steve
    Carpentieri, David
    Williams, James
    Acosta, Juan
    Southard, Richard
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (05) : e323 - e327
  • [33] BAP1, a tumor suppressor gene driving malignant mesothelioma
    Cheung, Mitchell
    Testa, Joseph R.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (03) : 270 - 278
  • [34] Somatic BAP1 and NF2 mutations in pleural malignant mesothelioma and their correlation with clinical phenotype
    Gennatas, S.
    Lu, S. K.
    Anbunathan, H.
    Popat, S.
    O'Brien, M.
    Lim, E.
    Fernandez, A. Montero
    Benepal, T.
    Nicholson, A. G.
    Lathrop, M.
    Moffatt, M.
    Cookson, W.
    Bowcock, A. M.
    LUNG CANCER, 2017, 103 : S25 - S26
  • [35] BAP1 loss in the diagnosis of malignant mesothelioma; review of a regional mesothelioma MDT
    Mcdill, H.
    Dipper, A.
    Bhatt, N.
    Clive, A.
    Maskell, N.
    Bibby, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [36] Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
    Cedres, S.
    Amair, F.
    Martinez-Marti, A.
    Navarro, A.
    Pardo, N.
    Remon-Masip, J.
    Miquel, J. M.
    Villacampa, G.
    Dienstmann, R.
    Felip Font, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S131 - S132
  • [37] QUALITY OF LIFE (QOL) IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) TREATED WITH CHEMOTHERAPY
    Van Meerbeeck, J.
    Gaafar, R.
    Manegold, C.
    Burgers, S.
    Coens, C.
    Legrand, C.
    Vincent, M.
    Giaccone, G.
    Bottomley, A.
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2141 - 2141
  • [38] A RETROSPECTIVE ANALYSIS OF SECOND-LINE CHEMOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Bramati, A.
    Moretti, A.
    Garassino, M. C.
    Califano, R.
    Farina, G.
    Lo Dico, M.
    Cinquini, M.
    Michetti, G. N.
    Tiseo, M.
    Zucali, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S103 - S103
  • [39] Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
    Pulford, Emily
    Huilgol, Kalyani
    Moffat, David
    Henderson, Douglas W.
    Klebe, Sonja
    DISEASE MARKERS, 2017, 2017
  • [40] Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
    Osmanbeyoglu, Hatice Ulku
    Palmer, Drake
    Sagan, April
    Sementino, Eleonora
    Becich, Michael J.
    Testa, Joseph R.
    CANCERS, 2022, 14 (22)
12345